Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Immunology

• Publication date

  2018-03-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1701622PMID 29531171
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Masterful Antibodies: Checkpoint Blockade

  2017cited by this paper
• MGUS to myeloma: a mysterious gammopathy of underexplored significance.

  2016cited by this paper
• Microenvironment-dependent growth of pre-neoplastic and malignant plasma cells in humanized mice

  2016cited by this paper
• PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

  2016cited by this paper
• Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells

  2016cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

  2015cited by this paper
• HLA-G: An Immune Checkpoint Molecule.

  2015cited by this paper
• Pathogenesis beyond the cancer clone(s) in multiple myeloma.

  2015cited by this paper
• The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study

  2015cited by this paper
• Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

  2015cited by this paper
• Immune checkpoint blockade in hematologic malignancies.

  2015cited by this paper
• PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

  2015cited by this paper
• S100 proteins in cancer

  2015cited by this paper
• Targeting the bone marrow microenvironment in multiple myeloma

  2015cited by this paper
• IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors

  2014cited by this paper
• Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking

  2014cited by this paper
• Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

  2014cited by this paper
• Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

  2014cited by this paper
• Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses

  2014cited by this paper
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  2013cited by this paper
• S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells

  2013cited by this paper
• Role of non-classical MHC class I molecules in cancer immunosuppression

  2013influential reference
• CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis.

  2012cited by this paper
• Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction

  2012cited by this paper
• Incorporating monoclonal antibodies into the therapy of multiple myeloma.

  2012cited by this paper
• Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma

  2012cited by this paper
• EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

  2011cited by this paper
• Defining the critical hurdles in cancer immunotherapy

  2011cited by this paper
• Multiple myeloma.

  2011cited by this paper
• Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.

  2011cited by this paper
• Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

  2011cited by this paper
• DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

  2009cited by this paper
• Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias.

  2009cited by this paper
• Immunoreceptor tyrosine‐based inhibition motifs: a quest in the past and future

  2008cited by this paper
• HLA Class I Molecules Regulate IFN-γ Production Induced in NK Cells by Target Cells, Viral Products, or Immature Dendritic Cells through the Inhibitory Receptor ILT2/CD85j1

  2008cited by this paper
• The extended human leukocyte receptor complex: diverse ways of modulating immune responses

  2008cited by this paper
• Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

  2008cited by this paper
• T-cell costimulation--biology, therapeutic potential, and challenges.

  2006cited by this paper
• Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

  2005cited by this paper
• Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib

  2004cited by this paper
• Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

  2003cited by this paper
• A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.

  2002cited by this paper
• Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily

  1999cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells

  1997cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications

  2025influential citation
• Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis

  2024cites this paper
• The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications

  2024cites this paper
• MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy

  2024cites this paper
• A Comprehensive Targeted Panel of 295 Genes: Unveiling Key Disease Initiating and Transformative Biomarkers in Multiple Myeloma

  2024cites this paper
• Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer

  2023cites this paper
• BDL-SP: A Bio-inspired DL model for the identification of altered Signaling Pathways in Multiple Myeloma using WES data.

  2023cites this paper
• Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma

  2022cites this paper
• Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy

  2022cites this paper
• Cross‐platform immunophenotyping of human peripheral blood mononuclear cells with four high‐dimensional flow cytometry panels

  2022cites this paper
• Multiple Myeloma Therapy: Emerging Trends and Challenges

  2022cites this paper
• Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma.

  2021cites this paper
• Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

  2021influential citation
• Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma

  2020cites this paper
• Nectin-2 Q 1 Expression on Malignant Plasma Cells is 4 Associated with Better Response to TIGIT Blockade in 5 Multiple Myeloma

  2020cites this paper
• Why Immunotherapy Fails in Multiple Myeloma

  2020cites this paper
• Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy

  2020cites this paper
• Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

  2020cites this paper
• The BLIMP1—EZH2 nexus in a non-Hodgkin lymphoma

  2020cites this paper
• Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma

  2020cites this paper
• Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma.

  2020cites this paper
• Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

  2020cites this paper
• Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma.

  2020cites this paper
• Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma

  2020cites this paper
• The BLIMP1 – EZH2 nexus in a non-Hodgkin lymphoma

  2019cites this paper